FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.

A positive recommendation from the CDC would allow Moderna's vaccine to compete against GSK and Pfizer, which launched their respective shots in the U.S. last fall. Pfizer's vaccine has so far lagged behind GSK's, but both shots have so far recorded hundreds of millions in sales.The approval demonstrates the versatility of Moderna's messenger RNA platform beyond treating Covid.

Moderna has said it expects to return to sales growth in 2025 and to break even by 2026, with the launch of new products.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever productThe decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
Sumber: CNBC - 🏆 12. / 72 Baca lebih lajut »

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever productThe decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product. 
Sumber: NBCLA - 🏆 319. / 59 Baca lebih lajut »